Results 71 to 80 of about 489 (130)

Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials [PDF]

Aims: Data on cardiac myosin inhibitors (CMIs) in obstructive hypertrophic cardiomyopathy (oHCM) are rapidly emerging. This systematic review and meta-analysis evaluated the efficacy and safety of CMIs in randomized placebo-controlled trials. Methods:
Coats, Caroline J., Goldie, Fraser C., Henderson, Alasdair D., Lee, Matthew M.Y., Masri, Ahmad, Olivotto, Iacopo   +5 more
core   +1 more source

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside [PDF]

, 2022
Coppini, Raffaele, Olivotto, Iacopo, Palandri, Chiara, Santini, Lorenzo   +3 more
core   +1 more source

Novel process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl) -2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide [PDF]

: The present invention relates to a novel process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, which is referred to as Aficamten and represented by the following structural
, Anonymous
core   +1 more source

Peak oxygen uptake vs ventilatory efficiency - in reply [PDF]

No abstract ...
Lee, Matthew M.Y., Lewis, Gregory D.
core   +1 more source

In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor

Xenobiotica
Aficamten, a small molecule selective inhibitor of cardiac myosin, was characterised in preclinical in vitro and in vivo studies.Protein binding in human plasma was 10.4% unbound and ranged from 1.6% to 24.9% unbound across species. Blood-to-plasma ratios ranged from 0.69 to 1.14 across species.
Rajaa, Sukhun, Peadar, Cremin, Donghong, Xu, Jeanelle, Zamora, Jennifer, Cheung, Luke, Ashcraft, Mark P, Grillo, Bradley P, Morgan   +7 more
openaire   +2 more sources

INIBIDORES DE MIOSINA E CARDIOMIOPATIA HIPERTRÓFICA: UMA POSSÍVEL SOLUÇÃO PARA ATLETAS DE ALTO RENDIMENTO? [PDF]

INTRODUÇÃO: A cardiomiopatia hipertrófica (CMH) é uma doença cardíaca de origem genética caracterizada por hipertrofia ventricular esquerda, podendo apresentar formas assintomáticas até insuficiência cardíaca refratária.
Laranjeiras, Mel Rodrigues, Piedade, Marina Cleto Miarelli, Teixeira, João Victor Marques, Valadares, Lícia Campos   +3 more
core   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects. [PDF]

Drug Des Devel Ther
Hou L, Lin B, Ji X, Huang A.
europepmc   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]

Int J Mol Sci
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.   +7 more
europepmc   +1 more source

Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy

JACC: Heart Failure
Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, Juan Pablo Costabel, Edileide de Barros Correia, Anne M. Dybro, Perry Elliott, Neal K. Lakdawala, Amy Mann, Ajith Nair, Michael E. Nassif, Steen H. Poulsen, Patricia Reant, P. Christian Schulze, Andrew Wang, Indrias Berhane, Stephen B. Heitner, Daniel L. Jacoby, Stuart Kupfer, Fady I. Malik, Lisa Meng, Regina Sohn, Amy Wohltman, Michael A. Fifer   +23 more
openaire   +1 more source

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Saleh D, Kim EY, Hussain K, Samhan A, Shi M, Meng Z, Schormann E, Bindra P, Cheema B, Fullenkamp DE, Baldridge AS, Puthumana JJ, Rigolin VH, Cremer PC, Flaherty JD, Choudhury L.   +15 more
europepmc   +1 more source